Proposing Bromo-Epi-Androsterone for Neurologic Long-COVID

• DOI: 10.20944/preprints202407.0115.v1
• Publication Date: 2024-07-02T08:18:49Z
• Authors: Coad Thomas Dow

The neurologic effects of long-COVID are a therapeutic challenge. This article discusses the immunologic manifestations of long-COVID and proposes a non-androgenic, synthetic analog of dehydroepiandrosterone (DHEA), bromo-epi-androsterone (BEA), as a candidate for clinical trials for this exigent collection of neurologic conditions. Moreover, because there is an association between long-COVID and Alzheimer’s disease, the evaluation of BEA in long-COVID may serve as a proxy for its effect on neuroinflammatory biomarkers of Alzheimer’s disease that are shared with long-COVID.